Third-Quarter Revenue Climbs to $493 Million with Adjusted EPS of $2.39
On November 5, 2026, premier biotechnology platform developer Halozyme Therapeutics, Inc. reported its financial and operational results for the third quarter of 2026, substantially outpacing Wall Street consensus projections. The San Diego-based biopharmaceutical firm disclosed total revenue of $493.0 million, representing a 39 percent year-over-year increase compared to $354.3 million recorded in the third quarter of 2025. Net income expanded 41 percent to $247.0 million, up from $175.2 million twelve months earlier. Non-GAAP diluted earnings per share reached $2.39, beating the average analyst estimate of $2.30.
Revenue momentum was driven primarily by rapid expansion across the company's high-margin royalty streams. Third-quarter royalty revenue surged 44 percent year over year to $341.0 million, compared to $236.0 million reported in the corresponding period of 2025. Halozyme's proprietary ENHANZE drug delivery technology—utilizing recombinant human hyaluronidase to temporarily degrade subcutaneous hyaluronan—is licensed by tier-one pharmaceutical developers, including Johnson & Johnson, Roche, and Bristol Myers Squibb. By converting lengthy multi-hour intravenous infusions into rapid subcutaneous injections administered in minutes, commercial partner therapies experienced sustained patient uptake across oncology and immunology clinics globally.
Royalty Revenue Advances 44% Driven by Broad Commercial Subcutaneous Adoption
Supported by accelerating partner product sales, Halozyme executive leadership raised its full-year 2026 financial guidance. Total revenue is currently projected to fall between $1.860 billion and $1.925 billion, reflecting annual expansion of 33 to 38 percent. Full-year royalty revenues are guided to reach between $1.235 billion and $1.255 billion, an increase of 42 to 45 percent over 2025 levels. Adjusted EBITDA is expected to reach $1.240 billion to $1.290 billion, while non-GAAP diluted EPS is projected at $8.75 to $9.05, even after absorbing approximately $60 million in new proprietary drug delivery investments.
Furthermore, Halozyme published a supplemental regulatory assessment on November 6, 2026, reaffirming that the Centers for Medicare & Medicaid Services (CMS) Medicare Drug Price Negotiation Program final rules will have zero to minimal impact on royalty revenue through at least 2035. Corporate legal and actuarial evaluations confirmed that partner co-formulations maintain distinct regulatory exclusivity and pricing protections, diminishing policy uncertainty across institutional investor portfolios.
Raising Full-Year 2026 Revenue Target to $1.925 Billion as Drug Price Impact Remains Minimal
Healthcare equity analysts noted that Halozyme's capital-light intellectual property licensing model yields exceptional cash flow conversion, with nine-month operating cash flow reaching $679.2 million. The steady addition of clinical pipeline candidates across global pharmaceutical alliances continues to compound long-term royalty visibility across multi-year patent horizons.